收藏切换
Mining and analysis of adverse event signals of sacituzumab govitecan based on the Food and Drug Administration adverse event reporting system database in the United States
收藏切换
Huiyu XU1, Yaodong YAN1, Ruizhe QI2, *
World Clinical Drug | 2025, 46(4) : 393 - 400
Less
收藏切换
World Clinical Drug | 2025, 46(4): 393-400
• Article •
Mining and analysis of adverse event signals of sacituzumab govitecan based on the Food and Drug Administration adverse event reporting system database in the United States
Full
Huiyu XU1, Yaodong YAN1, Ruizhe QI2, *
Affiliations
  • 1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China
  • 2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China
Published: 2025-04-10 doi: 10.13683/j.wph.2025.04.012
Outline
收藏切换
Objective

To explore and analyze the adverse drug event (ADE) signals of sacituzumab govitecan in the database of the Food and Drug Administration adverse event reporting system (FAERS) of the United States.

Method

Adverse event reports related to sacituzumab govitecan from the second quarter of 2020 to the first quarter of 2024 were selected from the United States FAERS database. The reporting odds ratio method in the ratio imbalance method in combination with the Bayesian confidence propagation neural network (BCPNN) method were used to conduct data mining and analysis.

Result

After screening, a total of 3 085 ADE reports were obtained. Among them, female patients accounted for a relatively large proportion (86.09%), and the age group was mainly 45~64 years old (25.35%). The reporting country was mainly the United States (34.20%). The outcome was mainly composed of mortality rate (26.65%) and hospitalization rate (28.75%). There were 145 positive signals related to ADE involving 26 systemic organ classifications.The frequency of occurrence of ADE signals was basically consistent with the instructions. The instructions do not mention serious adverse reactions such as hemorrhagic diarrhea, paralytic intestinal obstruction, large intestine perforation, febrile bone marrow aplasia and bone marrow failure, etc..

Conclusion

When doctors us sacituzumab govitecan in clinical practice, it is necessary to conduct an assessment for the patient's medication use. During the treatment period, new adverse reactions should be vigilant, and timely intervention should be carried out when abnormalities are detected.

Food and Drug Administration adverse event reporting system  /  sacituzumab govitecan  /  adverse drug event  /  signal mining
徐慧钰, 颜耀东, 祁瑞哲. 基于美国FAERS数据库中戈沙妥珠单抗的药物不良事件信号挖掘与分析. 世界临床药物, 2025 , 46 (4) : 393 -400 . DOI: 10.13683/j.wph.2025.04.012
Huiyu XU, Yaodong YAN, Ruizhe QI. Mining and analysis of adverse event signals of sacituzumab govitecan based on the Food and Drug Administration adverse event reporting system database in the United States[J]. World Clinical Drug, 2025 , 46 (4) : 393 -400 . DOI: 10.13683/j.wph.2025.04.012
Year 2025 volume 46 Issue 4
54
13
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.04.012
  • Receive Date:2024-09-12
  • Online Date:2026-11-09
  • Published:2025-04-10
Article Data
Affiliations
History
  • Received:2024-09-12
Funding
Affiliations
    1.Department of Pharmacy, Beijing Jiangong Hospital, Beijing 100054, China
    2.Department of Pharmacy, the Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.04.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT